Diabetes and Insulin Resistance in Older People

Medical Clinics of North America

Volumn 95, Issue 3, 2011, Pages 615-629

  Viljoen, Adie ^a,b   Sinclair, Alan J ^a  

^a UNIVERSITY OF BEDFORDSHIRE   (United Kingdom)

^b LISTER HOSPITAL   (United Kingdom)

Author keywords

Aged elderly; Diabetes mellitus; Diagnosis; Insulin resistance; Metabolic syndrome

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; LIPID;

AGING; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMORBIDITY; DIABETES MELLITUS; DIABETIC FOOT; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DIAGNOSTIC TEST; DISEASE ASSOCIATION; DISEASE COURSE; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN RESISTANCE; LIFESTYLE; METABOLIC SYNDROME X; MICROALBUMINURIA; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; REVIEW;

AGED; BLOOD GLUCOSE; CHRONIC DISEASE; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; HEALTH EDUCATION; HEALTH SERVICES FOR THE AGED; HUMANS; HYPERGLYCEMIA; INSULIN RESISTANCE; LIFE STYLE; MIDDLE AGED; PRIMARY PREVENTION; QUALITY OF LIFE; SOCIAL SUPPORT;

EID: 79955614042     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2011.02.003     Document Type: Review

References (50)

1. Fagot-Campagna A., Bourdel-Marchasson I., Simon D. Burden of diabetes in an aging population: prevalence, incidence, mortality, characteristics and quality of care. Diabetes Metab 2005, 31(Spec No 2):5S35-35S52.
2. McBean A.M., Li S., Gilbertson D.T., et al. Differences in diabetes prevalence, incidence, and mortality among the elderly of four racial/ethnic groups: whites, blacks, hispanics, and asians. Diabetes Care 2004, 27(10):2317-2324.
3. Diabetes U.K. Diabetes in the UK 2004 2004, Diabetes UK, London.
4. Ubink-Veltmaat L.J., Bilo H.J., Groenier K.H., et al. Prevalence, incidence and mortality of type 2 diabetes mellitus revisited: a prospective population-based study in The Netherlands (ZODIAC-1). Eur J Epidemiol 2003, 18:793-800.
5. The International Diabetes Federation atlas. 4th edition 2009, Available at:, Accessed March 21, 2011. http://www.diabetesatlas.org/content/regional-overview.
6. Bourdel-Marchasson I., Helmer C., Fagot-Campagna A., et al. Disability and quality of life in elderly people with diabetes. Diabetes Metab 2007, 33(Suppl 1):S66-S74.
7. Neil H.A., Thompson A.V., Thorogood M., et al. Diabetes in the elderly: the Oxford Community Diabetes Study. Diabet Med 1989, 6:608-613.
8. Melton L.J., Palumbo P.J., Chu C.P. Incidence of diabetes mellitus by clinical type. Diabetes Care 1981, 4(5):547-550.
9. Mølbak A.G., Christau B., Marner B., et al. Incidence of insulin-dependent diabetes mellitus in age groups over 30 years in Denmark. Diabet Med 1994, 11(7):650-655.
10. Lipton R.B., Liao Y., Cao G., et al. Determinants of incident non-insulin-dependent diabetes mellitus among blacks and whites in a national sample. The NHANES I Epidemiologic Follow-up Study. Am J Epidemiol 1992, 136:503-512.
11. Ferrannini E., Vichi S., Beck-Nielsen H., et al. Insulin action and age. European Group for the Study of Insulin Resistance (EGIR). Diabetes 1996, 45:947-953.
12. Pandit M.K., Burke J., Gustafson A.B., et al. Drug-induced disorders of glucose tolerance. Ann Intern Med 1993, 118(7):529-539.
13. Meneilly G.S., Cheung E., Tuokko H. Counterregulatory hormone responses to hypoglycemia in the elderly patient with diabetes. Diabetes 1994, 43(3):403-410.
14. Sacks D.B., Fonseca V., Goldfine A.B. Diabetes: advances and controversies. Clin Chem 2011, 57:147-149.
15. Kirkman M.S., Kendall D.M. HemoglobinA1c to diagnose diabetes: why the controversy over adding a new tool?. Clin Chem 2011, 57:255-257.
16. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997, 20:1183-1197.
17. International Expert Committee International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009, 32:1327-1334.
18. American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care 2010, 33(Suppl 1):S62-S69.
19. Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus Abbreviated report of a WHO Consultation Available at:, Accessed March 21, 2011. http://www.who.int/diabetes/publications/report-hba1c_2011.pdf.
20. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation 1999, Available at:, Accessed March 21, 2011. http://whqlibdoc.who.int/hq/1999/who_ncd_ncs_99.2.pdf.
21. Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults Executive summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
22. Alberti K.G., Zimmet P., Shaw J. Metabolic syndrome-a new world-wide definition. A Consensus statement from the International Diabetes Federation. Diabet Med 2006, 23(5):469-480.
23. Morley J.E. The metabolic syndrome and aging. J Gerontol A Biol Sci Med Sci 2004, 59:139-142.
24. Morley J.E., Sinclair A.J. The metabolic syndrome in older persons: a loosely defined constellation of symptoms or a distinct entity?. Age Ageing 2009, 38:494-497.
25. Fong D.S., Aiello L.P., Ferris F.L., et al. Diabetic retinopathy. Diabetes Care 2004, 27:2540-2553.
26. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993, 329:977-986.
27. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352:837-853.
28. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998, 317:703-713.
29. Massin P., Kaloustian E. The elderly diabetic's eyes. Diabetes Metab 2007, 33(Suppl 1):S4-S9.
30. Boulton A.J., Malik R.A., Arezzo J.C., et al. Diabetic somatic neuropathies. Diabetes Care 2004, 27:1458-1486.
31. American Diabetes Association Standards of medical care in diabetes-2011. Diabetes Care 2011, 34(Suppl 1):S11-S61.
32. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney Int 1995, 47:1703-1720.
33. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000, 355:253-259.
34. Lewis E.J., Hunsicker L.G., Bain R.P., et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993, 329:1456-1462.
35. Graham I., Atar D., Borch-Johnsen K., et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007, 14(Suppl 2):S1-S113.
36. British Cardiac Society, British Hypertension Society, Diabetes UK, et al. JBS 2: the Joint British Societies' guidelines for prevention of cardiovascular disease in clinical practice. Heart 2005, 91(Suppl V):v1-v52.
37. Holman R.R., Paul S.K., Bethel M.A., et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577-1589.
38. Nathan D.M., Cleary P.A., Backlund J.Y., et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005, 353:2643-2653.
39. Patel A., MacMahon S., Chalmers J., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572.
40. Gerstein H.C., Miller M.E., Byington R.P., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545-2559.
41. Constans T., Lecomte P. Non pharmacological treatments in elderly diabetics. Diabetes Metab 2007, 33(Suppl 1):S79-S86.
42. Schweizer A., Dejager S., Foley J.E., et al. Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥75 years: a pooled analysis from a database of clinical trials. Diabetes Obes Metab 2011, 13:55-64.
43. Viljoen A., Sinclair A. Safety and efficacy of rosiglitazone in the elderly diabetic patient. Vasc Health Risk Manag 2009, 5:389-395.
44. Sinclair A.J. Diabetes in old age. Textbook of diabetes 2010, 13-18. Wiley-Blackwell, Oxford (UK), Chapter 54. 4th edition. R. Holt, C.S. Cockram, A. Flyvberg (Eds.).
45. Beckett N.S., Peters R., Fletcher A.E., et al. HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008, 58:1887-1898.
46. Viljoen A., Wierzbicki A.S. Cardiovascular risk factors - Dyslipidaemia diabetes lipid therapies. Textbook of diabetes 2010, 672-683. Wiley-Blackwell, Oxford (UK), Chapter 40. 4th edition. R. Holt, C.S. Cockram, A. Flyvberg (Eds.).
47. Viljoen A. A practical approach to lipid management in the elderly. J Nutr Health Aging 2011, 15:65-70.
48. Kearney P.M., Blackwell L., Collins R., et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008, 371:117-125.
49. Cholesterol Treatment Trialists' (CTT) Collaborators Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278.
50. Viljoen A., Wierzbicki A.S. Enhanced LDL-C reduction: lower is better. Does it matter how?. Int J Clin Pract 2008, 62(4):518-520.